See more : Mr Price Group Limited (MRPZF) Income Statement Analysis – Financial Results
Complete financial analysis of Avanos Medical, Inc. (AVNS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avanos Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Jones Lang LaSalle Incorporated (JLL) Income Statement Analysis – Financial Results
- Semapa – Sociedade de Investimento e Gestão, SGPS, S.A. (SEM.LS) Income Statement Analysis – Financial Results
- Vision Corporation Limited (VISIONCO.BO) Income Statement Analysis – Financial Results
- Shin Heung Energy & Electronics Co.,Ltd. (243840.KQ) Income Statement Analysis – Financial Results
- Amita Technologies Inc. (5233.TWO) Income Statement Analysis – Financial Results
Avanos Medical, Inc. (AVNS)
About Avanos Medical, Inc.
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.30M | 820.00M | 744.60M | 714.80M | 697.60M | 652.30M | 611.60M | 1.59B | 1.57B | 1.67B | 1.68B | 1.68B | 1.66B |
| Cost of Revenue | 293.60M | 370.00M | 380.30M | 341.50M | 295.40M | 261.40M | 274.70M | 1.03B | 1.04B | 1.12B | 1.07B | 1.08B | 1.07B |
| Gross Profit | 379.70M | 450.00M | 364.30M | 373.30M | 402.20M | 390.90M | 336.90M | 557.90M | 531.60M | 548.60M | 612.20M | 602.50M | 590.80M |
| Gross Profit Ratio | 56.39% | 54.88% | 48.93% | 52.22% | 57.65% | 59.93% | 55.09% | 35.04% | 33.77% | 32.81% | 36.49% | 35.78% | 35.59% |
| Research & Development | 27.20M | 30.60M | 32.30M | 34.90M | 37.70M | 41.80M | 38.20M | 41.10M | 32.30M | 33.60M | 37.90M | 33.00M | 31.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 318.10M | 341.90M | 300.30M | 332.60M | 399.10M | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Other Expenses | 30.20M | 3.50M | 22.80M | 51.90M | 21.10M | 8.20M | 20.10M | 18.30M | 4.50M | -3.80M | -2.40M | -1.50M | -2.80M |
| Operating Expenses | 375.50M | 376.00M | 355.40M | 419.40M | 457.90M | 390.40M | 380.00M | 470.50M | 435.30M | 454.30M | 386.90M | 374.50M | 380.10M |
| Cost & Expenses | 669.10M | 746.00M | 735.70M | 760.90M | 753.30M | 651.80M | 654.70M | 1.50B | 1.48B | 1.58B | 1.45B | 1.46B | 1.45B |
| Interest Income | 2.90M | 1.20M | 200.00K | 1.20M | 6.70M | 7.80M | 2.50M | 600.00K | 300.00K | 2.90M | 2.60M | 2.60M | 4.10M |
| Interest Expense | 15.00M | 10.00M | 3.30M | 15.60M | 15.00M | 26.40M | 31.60M | 32.70M | 33.10M | 6.00M | 100.00K | 800.00K | 200.00K |
| Depreciation & Amortization | 46.10M | 41.10M | 38.30M | 42.90M | 36.90M | 33.50M | 40.00M | 41.00M | 65.40M | 85.40M | 69.20M | 57.60M | 51.10M |
| EBITDA | 50.60M | 77.80M | 8.90M | -2.00M | -12.10M | 65.70M | -600.00K | -65.50M | -76.50M | 179.70M | 297.10M | 288.20M | 265.90M |
| EBITDA Ratio | 7.52% | 14.99% | 6.37% | -0.28% | -1.73% | 6.41% | 3.09% | 9.62% | 10.29% | 10.92% | 17.71% | 17.11% | 16.02% |
| Operating Income | 4.20M | 74.00M | 8.90M | -46.10M | -55.70M | 500.00K | -43.10M | 87.40M | -377.70M | 94.30M | 225.30M | 228.00M | 210.70M |
| Operating Income Ratio | 0.62% | 9.02% | 1.20% | -6.45% | -7.98% | 0.08% | -7.05% | 5.49% | -23.99% | 5.64% | 13.43% | 13.54% | 12.69% |
| Total Other Income/Expenses | -12.10M | -8.80M | 44.80M | -14.40M | -8.30M | -18.60M | -29.10M | -32.10M | -274.80M | -3.10M | 2.50M | 1.80M | 3.90M |
| Income Before Tax | -7.90M | 65.20M | 5.80M | -60.50M | -64.00M | -18.10M | -72.20M | 55.30M | -410.50M | 91.20M | 227.80M | 229.80M | 214.60M |
| Income Before Tax Ratio | -1.17% | 7.95% | 0.78% | -8.46% | -9.17% | -2.77% | -11.81% | 3.47% | -26.07% | 5.45% | 13.58% | 13.65% | 12.93% |
| Income Tax Expense | 2.00M | 14.70M | 600.00K | -33.30M | -18.10M | -9.60M | -40.10M | 15.50M | 15.80M | 64.10M | 73.20M | 77.20M | 72.20M |
| Net Income | -61.80M | 50.50M | 6.30M | -27.20M | -45.90M | 57.50M | 79.30M | 39.80M | -426.30M | 27.10M | 154.60M | 152.60M | 142.40M |
| Net Income Ratio | -9.18% | 6.16% | 0.85% | -3.81% | -6.58% | 8.81% | 12.97% | 2.50% | -27.08% | 1.62% | 9.22% | 9.06% | 8.58% |
| EPS | -1.33 | 1.08 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| EPS Diluted | -1.33 | 1.07 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| Weighted Avg Shares Out | 46.60M | 46.90M | 48.10M | 47.80M | 47.60M | 47.20M | 46.52M | 46.60M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
| Weighted Avg Shares Out (Dil) | 46.60M | 47.30M | 48.60M | 47.80M | 47.60M | 47.20M | 46.80M | 47.00M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
Avanos Medical (AVNS) Q1 Earnings Beat Estimates (Revised)
Avanos Medical (AVNS) Q1 Earnings Lag Estimates
Avanos Medical, Inc. Announces First Quarter 2024 Results
Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
Avanos Medical, Inc. Announces Voluntary Recall in Response to Nurse Assist, LLC Sterile Water Medical Products Recall
Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2023 Results
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Avanos Medical, Inc. and Encourages Investors with Losses to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports